Literature DB >> 8829141

Prevention of cocaine-induced hyperactivity by a naloxone isomer with no opiate antagonist activity.

N Chatterjie1, G J Alexander, J A Sechzer, K W Lieberman.   

Abstract

Dextro-naloxone [(+)-naloxone], an isomer with almost no opiate antagonist activity and no effect on spontaneous locomotor activity, can reduce cocaine-induced hyperactivity in mice. The classical opiate antagonist, levo-naloxone [(-)-naloxone], is known to counteract the excitatory motor effects of amphetamine and cocaine, but it has been tacitly assumed that this action of levo-naloxone is dependent on its ability to antagonize endogenous opioids. Our finding that a naloxone isomer with little or no opioid antagonist activity is also able to inhibit the cocaine effect on spontaneous motility, calls for a reconsideration of this assumption.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8829141     DOI: 10.1007/bf02527726

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  16 in total

1.  Studies in the (+)-morphinan series. 5. Synthesis and biological properties of (+)-naloxone.

Authors:  I Iijima; J Minamikawa; A E Jacobson; A Brossi; K C Rice
Journal:  J Med Chem       Date:  1978-04       Impact factor: 7.446

2.  Weanling rats exposed prenatally to cocaine exhibit an increase in striatal D2 dopamine binding associated with an increase in ligand affinity.

Authors:  F M Scalzo; S F Ali; N A Frambes; L P Spear
Journal:  Pharmacol Biochem Behav       Date:  1990-10       Impact factor: 3.533

3.  Role of opioid antagonists in treating intravenous cocaine abuse.

Authors:  T R Kosten; H D Kleber; C Morgan
Journal:  Life Sci       Date:  1989       Impact factor: 5.037

Review 4.  Medical complications of cocaine abuse.

Authors:  L L Cregler; H Mark
Journal:  N Engl J Med       Date:  1986-12-04       Impact factor: 91.245

5.  Cocaine attenuates the severity of naloxone-precipitated opioid withdrawal.

Authors:  T A Kosten
Journal:  Life Sci       Date:  1990       Impact factor: 5.037

6.  Antiarrhythmic action of naloxone: direct, non-opiate effect on the rat heart.

Authors:  Y Sarne; I Hochman; M Eshed; E Oppenheimer
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

7.  Influence of naloxone upon motor activity induced by psychomotor stimulant drugs.

Authors:  D N Jones; S G Holtzman
Journal:  Psychopharmacology (Berl)       Date:  1994-03       Impact factor: 4.530

8.  Naloxone reduces amphetamine-induced stimulation of locomotor activity and in vivo dopamine release in the striatum and nucleus accumbens.

Authors:  M S Hooks; D N Jones; J B Justice; S G Holtzman
Journal:  Pharmacol Biochem Behav       Date:  1992-08       Impact factor: 3.533

9.  Opioid mediation of cocaine-induced hyperactivity and reinforcement.

Authors:  A A Houdi; M T Bardo; G R Van Loon
Journal:  Brain Res       Date:  1989-09-11       Impact factor: 3.252

10.  Prevention of hyperthermia-induced seizures in immature rats by a hydantoin derivative of naloxone.

Authors:  N Chatterjie; M L Laorden; M M Puig; G J Alexander
Journal:  Life Sci       Date:  1989       Impact factor: 5.037

View more
  3 in total

Review 1.  Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia.

Authors:  Mark R Hutchinson; Yehuda Shavit; Peter M Grace; Kenner C Rice; Steven F Maier; Linda R Watkins
Journal:  Pharmacol Rev       Date:  2011-07-13       Impact factor: 25.468

Review 2.  Neuropsychopharmacological understanding for therapeutic application of morphinans.

Authors:  Eun-Joo Shin; Jau-Shyong Hong; Hyoung-Chun Kim
Journal:  Arch Pharm Res       Date:  2010-10-30       Impact factor: 4.946

3.  Preliminary pharmacological evaluation of enantiomeric morphinans.

Authors:  Anna W Sromek; Brian A Provencher; Shayla Russell; Elena Chartoff; Brian I Knapp; Jean M Bidlack; John L Neumeyer
Journal:  ACS Chem Neurosci       Date:  2014-01-08       Impact factor: 4.418

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.